Oncology Institute (TOI) Cash from Financing Activities (2020 - 2026)

Oncology Institute has reported Cash from Financing Activities for 7 years, with the latest figure at -$28000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 99.41% year-over-year to -$28000.0; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 323.05% YoY), and the FY2025 full-year result was $11.6 million, up 430.96% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$28000.0, down from $3.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $105.4 million in Q3 2022, with the low at -$10.7 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of -$847000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 1317537.5% — and 2025, when it plunged 405.33%.
• Oncology Institute's Cash from Financing Activities stood at -$847000.0 in 2022, then tumbled by 110.27% to -$1.8 million in 2023, then surged by 90.79% to -$164000.0 in 2024, then jumped by 2376.83% to $3.7 million in 2025, then plunged by 100.75% to -$28000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$28000.0 (Q1 2026), $3.7 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.